Grant Opportunities

The 2018 Request for Application (RFA) is now open.

We are pleased to issue the 2018 RFA for neuroendocrine tumor research.

We are seeking investigators and teams of investigators from around the world, with the tools to study neuroendocrine cancers in innovative ways. We are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields. We are very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts in bioinformatics, bio-nanotechnology, or other relevant disciplines.

We continue to have an interest and expect to fund research in pancreatic and gastrointestinal NETs.

Applicants can apply via proposalCENTRAL only, to any of the three program that we offer:

• Accelerator Award (AA): A 4-year, $1,200,000 ($300K/year), grant.
• Investigator Award (IA): A 2-year, $300,000 ($150K/year), grant.
• Pilot Award (PA): A 1-year grant at either $50,000 or $100,00.

Please, go to https://proposalcentral.altum.com/ to see each program in more detail, and to apply.

For any questions regarding our RFA, please email us at grants@netrf.org

Continuation of Funding

(for existing grantees only)

Currently funded NETRF investigators with projects that are finishing during 2018 have the option to apply for continuation of funding. Investigators interested in applying under this category should get in touch with the Director of Research.

Cell Line Prize

We are currently not accepting applications for the cell line prize.
Please visit our site in 2018 for an update.

The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Neuroendocrine Tumor Research Foundation therefore wishes to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This challenge requires written documentation, detailed description of each cell line, and sample delivery.